You are here: Industry Insights > favipiravir

News List

FDC launches Favipiravir oral suspension expresspharma
July 13, 2021
FDC has launched oral suspension of Favipiravir to treat mild to moderate cases of COVID-19 in the country.
Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu) expresspharma
June 09, 2021
PMS interim data revealed no new safety signals or concerns till date and safety is in line with known side effects of the drug.
Bal Pharma launches BALflu (favipiravir) tablets in India expresspharma
May 25, 2021
Bal Pharma announced the launch of Favipiravir formulation in the Indian market, under the brand name BALflu.
Brinton Pharma triples production of favipiravir expresspharma
May 14, 2021
Brinton Pharmaceuticals informed that it has more than tripled up the production of Faviton (Favipiravir 400) tablets. Favipiravir is used as an oral antiviral therapy for mild to moderate cases of COVID-19.
Vivimed gets DGHI nod to manufacture, market favipiravir tablet in India expresspharma
May 11, 2021
Vivimed Labs announced the receipt of Government of India (Director General of Health Services) approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India.
MSN Laboratories launches Favilow (Faripiravir) 800 mg tablets expresspharma
April 29, 2021
The higher strength Favilow 800 mg is priced at Rs 144 per tablet and will be available across pharmacies.
Researchers at Strathclyde University study effect of Favipiravir against mild COVID-19 infections expresspharma
March 01, 2021
It must be taken within four days of a positive swab test and researchers will assess the effectiveness of the drug to help with symptoms and reduce the time it takes to recover from COVID-19.
Favipiravir shows significant improvement in time to clinical cure for mild to moderate COVID-19 expresspharma
November 25, 2020
These findings were observed in Phase 3 clinical trial conducted by Glenmark Pharmaceuticals and have been published by the International Journal of Infectious Diseases.
SEC asks CDSCO to submit adverse event report of death during Umifenovir trial expresspharma
October 16, 2020
The Subject Expert Committee (SEC) has asked CDSCO to submit data of the reported serious adverse event (SAE), a single death, from the clinical trials of the drug combination of Favipiravir + Umifenovir by Glenmark Pharmaceuticals.
Umifenovir addition gives no significant clinical benefit in COVID-19 treatment: Glenmark study expresspharma
October 10, 2020
The FAITH study enrolled a total of 158 hospitalised patients with moderate COVID-19 in India.

Previous page 1 2 3 4 5 6 Next page